Effect of remimazolam combined with dexmedetomidine in the treatment of emergence agitation in adult patients

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200055233

Enrollment

Unknown

Registered

2022-01-03

Start date

2021-12-31

Completion date

Unknown

Last updated

2023-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dexmedetomidine group:Nil

Remazolam combined with dexmedetomidine group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients with restlessness during recovery during elective surgery; 2. Aged 18-60 years; 3. ASA I-III grade; 4. Non-cardiac and craniocerebral surgery.

Exclusion criteria

Exclusion criteria: 1. Mental illness or long-term use of benzodiazepines; 2. Those who cannot communicate normally; 3. Pregnant patients.

Design outcomes

Primary

Measure	Time frame
The treatment time from starting medication to calming down agitation;	—

Secondary

Measure	Time frame
Riker sedation and agitation scores before treatment and 30min after administration;Blood oxygen saturation;The stay time in the PACU;Blood pressure;Heart rate;	—

Countries

China

Contacts

Public ContactWang Lingling

The First Affiliated Hospital of Zhengzhou University

yiming2406@126.com+86 13592408335

Outcome results